As of September 2026, SPDR Solactive Japan ETF is classified as not halal.
NOT HALAL
Is SPDR Solactive Japan ETF Halal?
Shariah Compliance Analysis of ZJPN ETF
US Equity Total Market
No. As of September 2026, SPDR Solactive Japan ETF (ZJPN) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. SPDR Solactive Japan ETF does not pass Musaffa's business and financial screening criteria.
ZJPN was created on 2014-06-11 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 107.72m in AUM and 324 holdings. ZJPN tracks a market-cap-weighted index of large- and midcap Japanese stocks.
SPDR Solactive Japan ETF (ZJPN) Chart
Key Statistics of SPDR Solactive Japan ETF (ZJPN)
Today's Open
-
AUM
-
Avg. Volume
-
Expense Ratio
-
P/E Ratio
-
P/B Ratio
-
FAQ's for SPDR Solactive Japan ETF (ZJPN)
As of September 2026, SPDR Solactive Japan ETF ZJPN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes SPDR Solactive Japan ETF using these criteria to determine its compliance status.
The Shariah compliance status of SPDR Solactive Japan ETF may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.
Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.
You can check the latest Shariah compliance status of SPDR Solactive Japan ETF on Musaffa’s ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.